PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (OCTBB: BJCT), a leading developer of needle-free drug delivery systems, today announced that it has retained the services of Mr. Snehal Patel, an experienced life science professional and financial advisor, to assist the company as it explores strategic alternatives, including the sale of the company. A sale of the company may not result in proceeds to the common shareholders, given the liquidation preferences of the preferred shareholders. Inquiries should be made to Mr. Patel at spatel@bioject.com or 203-434-3290.
